SCHEMBL9890790

SCHEMBL9890790

NC(=O)Cc1ccccc1-c1ccc(F)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.40
KCNN4 O15554 1/20 0.40
KCNA5 P22460 2/20 0.40
ALPL P05186 1/20 0.40
ALDH1A1 P00352 2/20 0.40
ICMT O60725 2/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
MAPK13 O15264 1/20 0.39
DAPK3 O43293 1/20 0.39
ROCK2 O75116 1/20 0.39
CHEK2 O96017 1/20 0.39
CDK1 P06493 1/20 0.39
CSF1R P07333 1/20 0.39
PIM1 P11309 1/20 0.39
FGFR1 P11362 1/20 0.39
PRKACA P17612 1/20 0.39
FGFR3 P22607 1/20 0.39
RPS6KB1 P23443 1/20 0.39
CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395238 0.88 ICMT (0.39) KCNN4ALDH1A1ICMTMAPK8SLC9A1
SCHEMBL2393136 0.88 SLC9A1 (0.42) PKMKCNN4KCNA5ICMTSLC9A1
SCHEMBL9890684 0.86 CXCL8 (0.50) KCNA5PTGER1
SCHEMBL2391854 0.85 ALDH1A1 (0.45) ALDH1A1MAPK8SLC9A1MAPTNPC1
SCHEMBL2393300 0.85 GRM2 (0.50) ALDH1A1ICMTPTGER1
SCHEMBL2395132 0.84 ICMT (0.39) KCNN4ALDH1A1ICMTMAPK8SLC9A1
SCHEMBL1726042 0.84 PKM (0.45) PKMKCNN4KCNA5ALPLALDH1A1
SCHEMBL9890738 0.84 ALDH1A1 (0.41) KCNN4ALPLALDH1A1ICMTSMN1; SMN2
SCHEMBL2393938 0.83 KCNA5 (0.37) PKMKCNN4KCNA5ALDH1A1ICMT
SCHEMBL2394997 0.82 DPP4 (0.40) PKMALDH1A1ICMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PKM 3929/4885KCNN4 256/4885KCNA5 41/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PKM 3929/4885KCNN4 256/4885KCNA5 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.